{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117256","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.716350+00:00","generated_at":"2026-06-08T04:42:50.484967+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cara: $83M cash, royalty deal up to $40M, oral DFK Phase 3 readouts 2023-2026","bullets":["Cash $83M as of Sep 30, 2023; royalty sale with HCRx for up to $40M ($37.5M expected Q4 2023).","KORSUVA injection launched with CSL Vifor/Fresenius; approved in US, EU, Japan; TDAPA expires Mar 31, 2024.","Oral DFK Phase 3: KIND1 AD topline Dec 2023; KICK1&2 CKD topline 2H2024; KOURAGE1 NP topline 2H2024.","No debt, 54M shares outstanding, cash runway into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117256","json":"https://secwatch.observer/filing/0001104659-23-117256.json","markdown":"https://secwatch.observer/filing/0001104659-23-117256.md","text":"https://secwatch.observer/filing/0001104659-23-117256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923117256/0001104659-23-117256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923117256/tm2330513d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:42:50.484967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}